CreatorsPublishersAdvertisers
View more in
Cancer

Treatment With KRd Plus Autologous Stem Cell Transplant Elicits Durable Survival Benefit in Myeloma

cancernetwork.com
 2021-09-09

Cover picture for the articlePatients with multiple myeloma with standard or high-risk cytogenic abnormalities who were treated with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplant experienced promising responses. A regimen consisting of carfilzomib, lenalidomide (Revlimid), and dexamethasone (KRd) plus autologous stem cell transplant (ASCT) plus maintenance KR resulted in durable responses...

www.cancernetwork.com

Comments / 0

Comments / 0